Toll-like receptor

Kymera Therapeutics Presents Clinical Data from the Phase 1 Trial of IRAK4 Degrader, KT-474 (SAR444656), at the European Academy of Dermatology and Venereology Symposium

Retrieved on: 
Donnerstag, Mai 18, 2023
PK, Human, PD, Toll-like receptor, Journal of the European Academy of Dermatology and Venereology, Atopic dermatitis, TPD, Inflammation, HS, European Academy of Allergy and Clinical Immunology, Patient, Hidradenitis suppurativa, Blood, Sanofi, AD, Therapy, Receptor (biochemistry), Skin, Safety, Pharmaceutical industry, Vaccine, IRAK4, Dermatology, Black Majesty, Venereology

WATERTOWN, Mass., May 18, 2023 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation (TPD) to deliver novel small molecule protein degrader medicines, today presented positive Phase 1 clinical data from its lead program, KT-474 (SAR444656), a potent, highly selective, orally bioavailable IRAK4 degrader. The Company delivered an oral presentation at the European Academy of Dermatology and Venereology (EADV) Symposium, taking place from May 18-20, 2023, in Seville, Spain.

Key Points: 
  • The Company delivered an oral presentation at the European Academy of Dermatology and Venereology (EADV) Symposium, taking place from May 18-20, 2023, in Seville, Spain.
  • IRAK4 is a key protein involved in inflammation mediated by the activation of toll-like receptors (TLRs) and IL-1 receptors (IL-1Rs).
  • Aberrant activation of these pathways is the underlying cause of multiple immune-inflammatory conditions.
  • “The KT-474 Phase 1 trial was a substantial accomplishment for Kymera, showcasing the high fidelity of PK/PD and safety translation from preclinical species to humans for our heterobifunctional degrader platform.

The Global Prebiotic Association Announces 2023 Young Researcher Fundamental and Applied Research Grant Winners

Retrieved on: 
Freitag, April 21, 2023
Single, University, Toll-like receptor, GPA, Synbiotics, Research, Doctor of Philosophy, Groningen, Nutritional science, Journal, Research fellow, University of Groningen, Applied science, Fundamental, Toll, University Medical Center Groningen, Woman, Carbohydrate Polymers, Pharmaceutical industry

CHICAGO, April 21, 2023 /PRNewswire/ -- The Global Prebiotic Association, the only global trade association serving as a resource for prebiotic education, insights, and awareness building, announced today its 2023 Young Researcher grant recipients.

Key Points: 
  • CHICAGO, April 21, 2023 /PRNewswire/ -- The Global Prebiotic Association, the only global trade association serving as a resource for prebiotic education, insights, and awareness building, announced today its 2023 Young Researcher grant recipients.
  • Grants were awarded in two categories – Fundamental and Applied Research.
  • Topics could cover any aspect of prebiotic research (primary authorship) including gut and other microbiomes and must have been original research published in a peer-reviewed journal.
  • The 2024 grant application period will open in November 2023 and will be open to researchers covering prebiotics and synbiotics.

Today's U.S. Electric Power Industry Course: Structure, Function, and Current Status of Renewable Energy, ISO Markets, and Power Transactions (Houston, United States - April 18-19, 2023) - ResearchAndMarkets.com

Retrieved on: 
Freitag, Januar 20, 2023
Alternative Energy, Energy, Toll-like receptor, NERC, Carnegie Mellon University, Common, California Community College Athletic Association, Marketing, Mechanics, Monolithic kernel, Utility, AGC, OASIS, Natural gas, Cfds, Var, RPM, Professional, Information and communications technology, NYMEX, Wind, ISO, FERC, Coal, ERCOT, Optical disc image, Name, Face, Non-bank financial institution, PJM, Risk management, LMP, Risk, Strategic planning, Delhi Transco Limited, Renewable energy, MISO, Electricity, FTR, ATC, Public utility, Electric power, Electric battery, Security (finance), Cryptocurrency, Distribution (marketing)

The "Today's U.S. Electric Power Industry, Renewable Energy, ISO Markets, and Power Transactions" training has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Today's U.S. Electric Power Industry, Renewable Energy, ISO Markets, and Power Transactions" training has been added to ResearchAndMarkets.com's offering.
  • If you want to truly understand the U.S. electric power industry, this course is for you.
  • Who the key players in the industry are, and why the industry is so difficult to restructure.
  • John Adamiak is President and Founder of PGS Energy Training and an expert in energy derivatives and electric power markets.

Curis Announces Additional Encouraging Clinical Data from TakeAim Leukemia Study of emavusertib (CA-4948) in Monotherapy R/R AML and hrMDS

Retrieved on: 
Montag, Dezember 12, 2022
Squamous cell carcinoma, FLT3, Lymphatic system, Dana–Farber Cancer Institute, Venetoclax, Cancer, Disease, BTK, Patient, COVID-19, AML, MDS, Patent, Risk, Form 10-K, Azacitidine, B-cell lymphoma, MYD88, Myelodysplastic syndrome, Multimedia, Toxic leukoencephalopathy, NCI, Security (finance), Toll-like receptor, Webcast, Food, MD, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Genentech, Roche, U2AF1, Form, Marketing, Mutation, Therapy, IL-1R, CRS, Biomarker, Research, CRADA, FDA, BCC, Safety, Hoffmann-La Roche, Acute myeloid leukemia, NF, TLR, Pharmaceutical industry, SF3B1, Curie Institute (Paris), Vismodegib, IRAK4

LEXINGTON, Mass., Dec. 12, 2022 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced positive updated clinical data from the ongoing open label Phase 1a dose escalation study of emavusertib (CA-4948), a novel, small molecule IRAK-4 inhibitor, as a monotherapy in patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) or high risk myelodysplastic syndromes (hrMDS) in both targeted and non-targeted populations. Patients in a targeted population are those with disease harboring U2AF1, SF3B1 (collectively "spliceosome") or FLT3 mutations. The company also announced positive initial data of emavusertib in combination with venetoclax in patients with AML or hrMDS that enrolled in the combination phase (Phase 1b) of the TakeAim Leukemia study prior to the partial clinical hold placed in April 2022.

Key Points: 
  • This represents 11 additional patients treated in targeted monotherapy populations and 13 additional patients in the non-targeted monotherapy population.
  • In addition to the monotherapy data, there are 4 patients with AML/hrMDS who have been treated with emavusertib in combination with venetoclax.
  • Previous data presented by Curis highlighted preliminary efficacy data of emavusertib in R/R AML/MDS patients whose disease is characterized by spliceosome or FLT3 mutation.
  • TakeAim Leukemia Study (NCT04278768) - This study is only enrolling in the monotherapy dose finding phase (phase 1a) of the study.

Dose Escalation Data from transcendIT-101, Ascendis Pharma’s Phase 1/2 Trial of TransCon™ TLR7/8 Agonist in Patients with Advanced Solid Tumors, Presented at SITC 2022

Retrieved on: 
Freitag, November 11, 2022
Southern Transcon, Melanoma, SITC, Society for Immunotherapy of Cancer, Annual report, Investment, Cancer, Society, Pembrolizumab, University of Pittsburgh Medical Center, U.S. Securities and Exchange Commission, Immunotherapy, Toxicity, GLOBE, Research, Toll-like receptor, TLR, Drug, Senior, SEC, Immune system, CSCC, Safety, Neoplasm, Resiquimod, Forward-looking statement, Poster, Science, SCC, COVID-19, Head, University, Nasdaq, B cell, Vii, Compliance, Pharmaceutical industry, Vaccine, Fine chemical, Princeton University, Patient

COPENHAGEN, Denmark, Nov. 11, 2022 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today disclosed new data from the dose-escalation portion of transcendIT-101, the company’s Phase 1/2 open-label, multi-center trial of TransCon TLR7/8 Agonist in patients with advanced solid tumors. TransCon TLR7/8 Agonist is an investigational long-acting prodrug designed to provide sustained, localized release over weeks of resiquimod (a potent immune response modifier with clinically demonstrated anti-tumor activity) with low systemic exposure.

Key Points: 
  • The dose escalation data from transcendIT-101, presented by Diwakar Davar, M.D.
  • The recommended Phase 2 dose was declared at 0.5 mg/lesion for up to two lesions.
  • SITC 2022 registrants can obtain the poster (#763) and oral presentation slides, both titled Phase 1/2, Open-Label, Multicenter, First-in-Human Dose Escalation and Dose Expansion Study of TransCon TLR7/8 Agonist Alone or in Combination With Pembrolizumab in Patients With Locally Advanced or Metastatic Solid Tumor Malignancies: Initial Results From Phase 1 Dose Escalation (transcendIT-101) Trial, from the SITC 2022 event website: https://www.sitcancer.org/2022/home .
  • Ascendis, Ascendis Pharma, the Ascendis Pharma logo, the company logo, and TransCon are trademarks owned by the Ascendis Pharma Group.

Ascendis Pharma Announces Recommended Phase 2 Dose and Cohort Expansion for transcendIT-101, a Phase 1/2 Clinical Trial of TransCon™ TLR7/8 Agonist in Solid Tumors

Retrieved on: 
Montag, Oktober 3, 2022
HNSCC, Southern Transcon, Melanoma, U.S. Securities and Exchange Commission, B cell, Society, SEC, Physician, Technology, Nasdaq, Research, CSCC, Toll-like receptor, Immunotherapy, Head, Neoplasm, COVID-19, Annual report, TLR, Resiquimod, Society for Immunotherapy of Cancer, Safety, Science, Patient, SITC, Forward-looking statement, Investment, Vii, Drug, GLOBE, Senior, Pharmaceutical industry, Vaccine, Fine chemical, Princeton University, Cancer

COPENHAGEN, Denmark, Oct. 03, 2022 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced completion of the dose-escalation portion and recommendation of the Phase 2 dose in transcendIT-101, a Phase 1/2 clinical trial to evaluate the safety and efficacy of TransCon TLR7/8 Agonist in locally advanced or metastatic solid tumors, alone or in combination with pembrolizumab. TransCon TLR7/8 Agonist is a novel investigational product candidate designed for sustained, localized release of resiquimod (a potent immune-response modifier with clinically demonstrated anti-tumor activity) with low systemic exposure. The abstract for the dose-escalation topline data was accepted for an oral presentation at SITC 2022, the annual meeting of the Society for Immunotherapy of Cancer being held November 8-12 in Boston.

Key Points: 
  • All patients in the dose escalation portion of the trial had advanced or metastatic solid-tumors and had progressed on prior treatments.
  • The cohorts include head and neck squamous-cell carcinoma (HNSCC); other HPV-associated cancers; melanoma; and cutaneous squamous cell carcinoma (cSCC).
  • In this portion of the study, all participants will be treated every three weeks with intratumoral TransCon TLR7/8 Agonist in combination with intravenous pembrolizumab.
  • Ascendis, Ascendis Pharma, the Ascendis Pharma logo, the company logo and TransCon are trademarks owned by the Ascendis Pharma Group.

2022 Tang Prize in Biopharmaceutical Science Honors Three Scientists for Developing COVID-19 mRNA Vaccines

Retrieved on: 
Sonntag, Juni 19, 2022
RNA, National Institutes of Health, University, Animal, Science, Lipid, Infection, Protein, Health, Deoxyribonucleoside, BioNTech, Nanoparticle, Life, Patent, COVID-19, Vaccine, Inflammation, Nobel Prize, Death, Technology, Antigen, DNA, Pfizer–BioNTech COVID-19 vaccine, Tang Prize, Immune system, LNP, Ribose, Ribonucleoside, Cell, NIH, Doctor of Philosophy, Civilization, Climate change, FDA, World, Nucleoside, Virus, HIV, Rule of law, Coronavirus, Physics, Multimedia, COVID, RNA transfection, Antibody, Zika virus, Research, World Health Organization's response to the COVID-19 pandemic, Cancer, Toll-like receptor, LN, Severe acute respiratory syndrome coronavirus 2, Paganini Competition, Deoxyribose, Sustainable development, Membrane, National, Pharmaceutical industry, Moderna, Sinology, Nobel

After much waiting, names of the latest winners were finally announced at ten (GMT+8) in the morning of June 19.

Key Points: 
  • After much waiting, names of the latest winners were finally announced at ten (GMT+8) in the morning of June 19.
  • Fortunately, it took Pfizer/BioNTech and Moderna less than 12 months to successfully develop vaccines against SARS-CoV-2.
  • While Dr. Kariko and Dr. Weissman found a way to reduce the immunogenicityiof mRNA, Dr. Cullis is credited with designing lipid nanoparticles for the delivery of mRNA vaccines.
  • These mRNA molecules are encapsulated in lipid nanoparticles and delivered effectively into the cells.

Statera Biopharma Advances Next-Gen Proprietary Compositions Based on STAT-200 Platform

Retrieved on: 
Montag, März 7, 2022
Entolimod, Computational chemistry, Stephen Wilson, Patient, Research, Virus, RIDE, TLR5, Antibody, Doctor of Philosophy, Pancreatic cancer, TLR4, Fibromyalgia, Homeostasis, SEC, Company, TLR, Budget, COVID-19, Cancer, Inflammation, Toll-like receptor, Autoimmunity, Multiple sclerosis, Â, Hematology, Nasdaq, TLR9, Receptor (biochemistry), GLOBE, Vaccine, Pharmaceutical industry

FORT COLLINS, Colo., March 07, 2022 (GLOBE NEWSWIRE) -- Statera Biopharma, Inc. (Nasdaq: STAB), a leading biopharmaceutical company creating next-generation immune therapies that focus on immune restoration and homeostasis, today announced advancement of its next-gen research activities that builds upon the immune modulation activity of STAT-200 on Toll-Like Receptors (TLRs) to improve drug characteristics and clinical benefit beyond opioid receptors.

Key Points: 
  • Stateras discovery platform identifies novel compositions that build upon STAT-200 by modulating multiple cellular targets, versus one, to restore cellular homeostasis.
  • These findings have led to the selection of promising new compositions with the potential to treat a range of inflammatory-related diseases.
  • The platform could not have existed before the discovery of the effect of STAT-200 on TLRs, said Stephen Wilson, PhD, Chief Innovation Officer at Statera.
  • Statera Biopharma, Inc. (formerly Cytocom, Inc.) is a clinical-stage biopharmaceutical company developing novel immunotherapies targeting autoimmune, neutropenia/anemia, emerging viruses and cancers based on a proprietary platform designed to rebalance the bodys immune system and restore homeostasis.

Ascendis Pharma A/S Provides Update on Vision 3x3 Strategic Roadmap at 40th Annual J.P. Morgan Healthcare Conference

Retrieved on: 
Montag, Januar 10, 2022
J. P. Morgan, Marketing Authorisation Application, Hormone, MAA, B cell, HP, NDA, Annual report, XV, FDA, TLR, European, Investigational New Drug, Toll-like receptor, Failure, New Drug Application, Committee for Medicinal Products for Human Use, Turner syndrome, U.S. Securities and Exchange Commission, Science, Resiquimod, Company, Technology, U.S. FDA, SEC, Safety, European Medicines Agency, Committee, Investor, Investment, Patient, Pathway, Growth hormone, Research, Nasdaq, State, COVID-19, GLOBE, Achondroplasia, Investor relations, CHMP, Marketing, Conference, Adult, IND, Forward-looking statement, Southern Transcon, Prescription, European Directive on Traditional Herbal Medicinal Products, Xi, EMA, Fine chemical, Pharmaceutical industry, Princeton University, Foresight

COPENHAGEN, Denmark, Jan. 10, 2022 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that the Company will today provide an update on its Vision 3x3 and planned 2022 key milestones at the 40th Annual J.P. Morgan Healthcare Conference.

Key Points: 
  • COPENHAGEN, Denmark, Jan. 10, 2022 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that the Company will today provide an update on its Vision 3x3 and planned 2022 key milestones at the 40th Annual J.P. Morgan Healthcare Conference.
  • We believe the clinical readouts will demonstrate our ability to deliver therapies that make a meaningful impact on patients lives.
  • Presentation at J.P. Morgan Healthcare Conference on Monday, January 10th
    The live webcast of the J.P. Morgan presentation will be available on the Investors & News section of the Ascendis Pharma website at www.ascendispharma.com .
  • Ascendis, Ascendis Pharma, the Ascendis Pharma logo, the Company logo, TransCon, and SKYTROFA are trademarks owned by the Ascendis Pharma Group.

Ascendis Pharma A/S Presents New Non-Clinical Data for TransCon™ TLR7/8 Agonist Oncology Program at SITC 2021

Retrieved on: 
Dienstag, November 9, 2021
Safety, SITC, Index (publishing), Science, TLR, Neoplasm, Toll-like receptor, U.S. Securities and Exchange Commission, Hormone, Resiquimod, Technology, Society, Investment, Pembrolizumab, COVID-19, MTD, Research, Forward-looking statement, Annual report, Maxima and minima, Southern Transcon, Society for Immunotherapy of Cancer, GLOBE, SEC, Toxicity, Immunotherapy, B cell, Nasdaq, Patient, Autoinjector, Vaccine, Pharmaceutical industry, Fine chemical

COPENHAGEN, Denmark, Nov. 09, 2021 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced two poster presentations featuring new non-clinical data for its investigational TransCon™ TLR7/8 Agonist product candidate at SITC 2021, the annual meeting for the Society for Immunotherapy of Cancer taking place virtually and in person November 10-14 in Washington, D.C.

Key Points: 
  • The data show that, as designed, TransCon TLR7/8 Agonist, which leverages the Companys innovative TransCon hydrogel technology, provides sustained activation of both innate and adaptive immune mechanisms with low systemic cytokine levels.
  • Ascendis Pharma is currently conducting a Phase 1/2 study, called the transcendIT-101 Study (ClinicalTrials.gov Identifier: NCT04799054), to evaluate TransCon TLR7/8 Agonist as monotherapy or in combination with pembrolizumab in dose escalation and dose expansion cohorts.
  • Ascendis Pharma is applying its innovative platform technology to build a leading, fully integrated biopharma company focused on making a meaningful difference in patients lives.
  • Ascendis, Ascendis Pharma, the Ascendis Pharma logo, the company logo, TransCon, and SKYTROFA are trademarks owned by the Ascendis Pharma Group.